
Johannes Lorscheider

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7707801/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Annals of Neurology, 2017, 81, 857-870.	5.3	768
2	Defining secondary progressive multiple sclerosis. Brain, 2016, 139, 2395-2405.	7.6	281
3	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurology, The, 2022, 21, 246-257.	10.2	210
4	Predictors of longâ€ŧerm disability accrual in relapseâ€onset multiple sclerosis. Annals of Neurology, 2016, 80, 89-100.	5.3	158
5	Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology, 2015, 84, 1639-1643.	1.1	153
6	T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Neurology, 2013, 81, 174-181.	1.1	64
7	Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis. JAMA Neurology, 2019, 76, 274.	9.0	56
8	Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 777-785.	3.0	46
9	Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurology, 2022, 79, 682.	9.0	41
10	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 2017, 89, 1050-1059.	1.1	38
11	The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PLoS ONE, 2016, 11, e0152347.	2.5	38
12	A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. Multiple Sclerosis Journal, 2019, 25, 1682-1685.	3.0	32
13	Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment. European Journal of Neurology, 2020, 27, 1066-1075.	3.3	21
14	Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study. Journal of Medical Internet Research, 2021, 23, e30394.	4.3	21
15	Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis. Journal of Neurology, 2021, 268, 941-949.	3.6	16
16	The BAR Domain Protein PICK1 Regulates Cell Recognition and Morphogenesis by Interacting with Neph Proteins. Molecular and Cellular Biology, 2011, 31, 3241-3251.	2.3	14
17	Accurate classification of secondary progression in multiple sclerosis using a decision tree. Multiple Sclerosis Journal, 2021, 27, 1240-1249.	3.0	14
18	Antiâ€inflammatory diseaseâ€modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. European Journal of Neurology, 2019, 26, 363-370.	3.3	12

#	Article	IF	CITATIONS
19	Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate. Multiple Sclerosis Journal, 2021, 27, 439-448.	3.0	8
20	Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials. Multiple Sclerosis Journal, 2020, 26, 993-996.	3.0	6
21	Endovascular Treatment for Acute Ischemic Stroke With or Without General Anesthesia: A Matched Comparison. Stroke, 2022, 53, 1520-1529.	2.0	6
22	Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	3
23	Hypothyroidism manifesting as multiple cranial neuropathies: a case report. Journal of Medical Case Reports, 2019, 13, 180.	0.8	2
24	PML with dimethyl fumarate—No convincing case against natalizumab. Multiple Sclerosis Journal, 2019, 25, 1687-1688.	3.0	1
25	Acute Polyradiculomyelitis With Spinal Cord Gray Matter Lesions: A Report of Two Cases. Frontiers in Neurology, 2021, 12, 721669.	2.4	1
26	When does a heap become a heap?. Multiple Sclerosis Journal, 2021, 27, 329-330.	3.0	0